

AKT2 Antibody
Affinity Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP7029E

Specification

AKT2 Antibody - Product Information

Application	IF, WB, FC,E
Primary Accession	P31751
Reactivity	Human, Mouse
Host	Rabbit
Clonality	Polyclonal
Isotype	Rabbit IgG
Calculated MW	55769

AKT2 Antibody - Additional Information

Gene ID 208

Other Names

RAC-beta serine/threonine-protein kinase, Protein kinase Akt-2, Protein kinase B beta, PKB beta, RAC-PK-beta, AKT2

Target/Specificity

This AKT2 antibody is generated from rabbits immunized with human AKT2 recombinant protein.

Dilution

IF~~1:10~50
WB~~1:1000
FC~~1:10~50

Format

Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.

Storage

Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

AKT2 Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

AKT2 Antibody - Protein Information

Name AKT2 ([HGNC:392](#))

Function Serine/threonine kinase closely related to AKT1 and AKT3. All 3 enzymes, AKT1, AKT2 and AKT3, are collectively known as AKT kinase. AKT regulates many processes including metabolism, proliferation, cell survival, growth and angiogenesis, through the phosphorylation of a

range of downstream substrates. Over 100 substrates have been reported so far, although for most of them, the precise AKT kinase catalyzing the reaction was not specified. AKT regulates glucose uptake by mediating insulin-induced translocation of the SLC2A4/GLUT4 glucose transporter to the cell surface. Phosphorylation of PTPN1 at 'Ser-50' negatively modulates its phosphatase activity preventing dephosphorylation of the insulin receptor and the attenuation of insulin signaling. Phosphorylation of TBC1D4 triggers the binding of this effector to inhibitory 14-3-3 proteins, which is required for insulin-stimulated glucose transport. AKT also regulates the storage of glucose in the form of glycogen by phosphorylating GSK3A at 'Ser-21' and GSK3B at 'Ser-9', resulting in inhibition of its kinase activity. Phosphorylation of GSK3 isoforms by AKT is also thought to be one mechanism by which cell proliferation is driven. AKT regulates also cell survival via the phosphorylation of MAP3K5 (apoptosis signal- related kinase). Phosphorylation of 'Ser-83' decreases MAP3K5 kinase activity stimulated by oxidative stress and thereby prevents apoptosis. AKT mediates insulin-stimulated protein synthesis by phosphorylating TSC2 at 'Ser-939' and 'Thr-1462', thereby activating mTORC1 signaling and leading to both phosphorylation of 4E-BP1 and in activation of RPS6KB1. AKT is involved in the phosphorylation of members of the FOXO factors (Forkhead family of transcription factors), leading to binding of 14-3-3 proteins and cytoplasmic localization. In particular, FOXO1 is phosphorylated at 'Thr-24', 'Ser-256' and 'Ser-319'. FOXO3 and FOXO4 are phosphorylated on equivalent sites. AKT has an important role in the regulation of NF-kappa-B-dependent gene transcription and positively regulates the activity of CREB1 (cyclic AMP (cAMP)-response element binding protein). The phosphorylation of CREB1 induces the binding of accessory proteins that are necessary for the transcription of pro-survival genes such as BCL2 and MCL1. AKT phosphorylates 'Ser- 454' on ATP citrate lyase (ACLY), thereby potentially regulating ACLY activity and fatty acid synthesis. Activates the 3B isoform of cyclic nucleotide phosphodiesterase (PDE3B) via phosphorylation of 'Ser-273', resulting in reduced cyclic AMP levels and inhibition of lipolysis. Phosphorylates PIKFYVE on 'Ser-318', which results in increased PI(3)P- 5 activity. The Rho GTPase-activating protein DLC1 is another substrate and its phosphorylation is implicated in the regulation cell proliferation and cell growth. AKT plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. Signals downstream of phosphatidylinositol 3-kinase (PI(3)K) to mediate the effects of various growth factors such as platelet- derived growth factor (PDGF), epidermal growth factor (EGF), insulin and insulin-like growth factor 1 (IGF1). AKT mediates the antiapoptotic effects of IGF1. Essential for the SPATA13-mediated regulation of cell migration and adhesion assembly and disassembly. May be involved in the regulation of the placental development (PubMed:[21432781](#), PubMed:[21620960](#)). In response to lysophosphatidic acid stimulation, inhibits the ciliogenesis cascade. In this context, phosphorylates WDR44, hence stabilizing its interaction with Rab11 and preventing the formation of the ciliogenic Rab11-FIP3-RAB3IP complex. Also phosphorylates RAB3IP/Rabin8, thus may affect RAB3IP guanine nucleotide exchange factor (GEF) activity toward Rab8, which is important for cilia growth (PubMed:[31204173](#)). Phosphorylates PKP1, facilitating its interaction with YWHAG and translocation to the nucleus, ultimately resulting in a reduction in keratinocyte intercellular adhesion (By similarity). Phosphorylation of PKP1 increases PKP1 protein stability, translocation to the cytoplasm away from desmosome plaques and PKP1- driven cap-dependent translation (PubMed:[23444369](#)).

Cellular Location

Cytoplasm. Nucleus Cell membrane; Peripheral membrane protein. Early endosome {ECO:0000250|UniProtKB:Q60823}. Note=Through binding of the N-terminal PH domain to phosphatidylinositol (3,4,5)-trisphosphate (PtdIns(3,4,5)P3) or phosphatidylinositol (3,4)-bisphosphate (PtdIns(3,4)P2), recruited to the plasma membrane. Cell membrane recruitment is facilitated by interaction with CLIP3. Colocalizes with WDFY2 in early endosomes (By similarity). Localizes within both nucleus and cytoplasm in proliferative primary myoblasts and mostly within the nucleus of differentiated primary myoblasts (PubMed:17565718) {ECO:0000250|UniProtKB:Q60823, ECO:0000269|PubMed:17565718}

Tissue Location


Widely expressed. Expressed in myoblasts (PubMed:17565718).

AKT2 Antibody - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


AKT2 Antibody - Images




Confocal immunofluorescent analysis of AKT2 Antibody (Cat#AP7029e) with 293 cells followed by Alexa Fluor 488-conjugated goat anti-rabbit IgG (green). Actin filaments have been labeled with Alexa Fluor 555 phalloidin (red). DAPI was used to stain the cell nuclei (blue).



Western blot analysis of AKT2 Antibody (Cat. #AP7029e) in NCI-H460 cell line lysates (35ug/lane). AKT2 (arrow) was detected using the purified Pab.



Western blot analysis of AKT2 Antibody (Cat. #AP7029e) in mouse brain tissue lysates (35ug/lane). AKT2 (arrow) was detected using the purified Pab.



AKT2 Antibody (Cat. #AP7029e) flow cytometric analysis of NCI-H460 cells (right histogram) compared to a negative control cell (left histogram). FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

AKT2 Antibody - Background

AKT2 is a putative oncogenic protein belonging to a subfamily of serine/threonine kinases containing SH2-like (Src homology 2-like) domains. Furthermore, AKT2 was shown to be amplified and overexpressed in 2 of 8 ovarian carcinoma cell lines and 2 of 15 primary ovarian tumors. Overexpression of AKT2 contributes to the malignant phenotype of a subset of human ductal pancreatic cancers. AKT2 is a general protein kinase capable of phosphorylating several known proteins.

AKT2 Antibody - References

Vojtek, A.B., et al., *Mol. Cell. Biol.* 23(13):4417-4427 (2003). Yuan, Z.Q., et al., *J. Biol. Chem.* 278(26):23432-23440 (2003). Jones, D.T., et al., *Blood* 101(8):3174-3180 (2003). Brozinick, J.T. Jr., et al., *Diabetes* 52(4):935-941 (2003). Miyakawa, M., et al., *Endocr. J.* 50(1):77-83 (2003).